Is The Testing Of All Babies In Italy For Coeliac Disease And Type 1 Diabetes Having Any Effects?
I asked Google AI, the question in the title of this post and received this reply.
Italy’s law (Law 130/2023) targets children aged 1 to 17 rather than newborns. Pilot screening programs (like D1Ce Screen) show major positive effects: they successfully catch hidden cases early—finding coeliac antibodies in nearly 3% of children and type 1 diabetes markers in 0.8%—which dramatically cuts down dangerous emergency complications like severe diabetic ketoacidosis at diagnosis.
Key Findings and Effects
Early Detection: Finds silent or pre-symptomatic cases that standard symptom-based testing misses.
Reduced Complications: Lowers severe diabetic ketoacidosis rates by up to 50% when type 1 diabetes is caught early.
High Prevalence Insights: Pilot data show coeliac markers reach nearly 2.8–2.9% in children, higher than previous global estimates.
Healthcare Feasibility: Proves that capillary blood collection through primary care pediatricians is organized and practical on a national scale.
The testing appears to be successful in Italy.
The Anonymous Widower 